ArticleTalanta2022
Aptamer/antibody sandwich method for digital detection of SARS-CoV2 nucleocapsid protein.
Article in Talanta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- An Engineered Supramolecular Pathway for Enhanced Electrochemiluminescence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dual-mode aptamer-driven biosensing platform for ultrasensitive and mutation-resilient detection of the SARS-CoV-2 nucleocapsid protein.Genes & diseases · 2026Article
- A paper-based immunoassay with signal amplification for the sensitive detection of nucleocapsid protein toward the diagnosis of long COVID.The Analyst · 2026Article
- Article
- Rapid and accurate detection of SARS-CoV-2 spike protein by aptamer conformation change based on a reusable aptasensor.Mikrochimica acta · 2025Article
- Performance of protein N linear epitopes in serodiagnosis of COVID-19 infection.BioImpacts : BI · 2025Article
- Current Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance Platforms.Current medicinal chemistry · 2025Review
- A Double-Stranded Aptamer for Highly Sensitive Fluorescent Detection of Glutathione S-Transferases.Biosensors · 2024Article
- Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications.Biosensors · 2024Review
- CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- Aptamers: precision tools for diagnosing and treating infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Highly sensitive digital detection of SARS-CoV-2 nucleocapsid protein through single-molecule counting.Analytical and bioanalytical chemistry · 2023Article
- Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.Trends in biotechnology · 2023Review
- Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein-binding epitopes for label-free COVID-19 diagnostics.Molecular therapy. Nucleic acids · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Capabilities of Double-Resonance LPG and SPR Methods for Hypersensitive Detection of SARS-CoV-2 Structural Proteins: A Comparative Study.Biosensors · 2023Article
- A New Method for Abrin Detection Based on the Interaction between Target Molecules and Fluorescently Labeled Aptamers on Magnetic Microspheres.Materials (Basel, Switzerland) · 2022Article
- Microfluidics Technology in SARS-CoV-2 Diagnosis and Beyond: A Systematic Review.Life (Basel, Switzerland) · 2022Review
- Microfluidics-Based Biosensing Platforms: Emerging Frontiers in Point-of-Care Testing SARS-CoV-2 and Seroprevalence.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleocapsid protein (N protein) is the most abundant protein in SARS-CoV2 and is highly conserved, and there are no homologous proteins in the human body, making it an ideal biomarker for the early diagnosis of SARS-CoV2. However, early detection of clinical specimens for SARS-CoV2 remains a challenge due to false-negative results with viral RNA and host antibodies based testing. In this manuscript, a microfluidic chip with femtoliter-sized wells was fabricated for the sensitive digital detection of N protein. Briefly, β-galactosidase (β-Gal)-linked antibody/N protein/aptamer immunocomplexes were formed on magnetic beads (MBs). Afterwards, the MBs and β-Gal substrate fluorescein-di-β-d-galactopyranoside (FDG) were injected into the chip together. Each well of the chip would only hold one MB as confined by the diameter of the wells. The MBs in the wells were sealed by fluorocarbon oil, which confines the fluorescent (FL) product generated from the reaction between β-Gal and FDG in the individual femtoliter-sized well and creates a locally high concentration of the FL product. The FL images of the wells were acquired using a conventional inverted FL microscope. The number of FL wells with MBs (FL wells number) and the number of wells with MBs (MBs wells number) were counted, respectively. The percentage of FL wells was calculated by dividing (FL wells number) by (MBs wells number). The higher the percentage of FL wells, the higher the N protein concentration. The detection limit of this digital method for N protein was 33.28 pg/mL, which was 300 times lower than traditional double-antibody sandwich based enzyme-linked immunosorbent assay (ELISA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.